Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 40Gastrointestinal 18Breast 15Thoracic 14Head & Neck 7Genitourinary 6Dermatologic 6Sarcoma 5Plasma cell 4Other solid neoplasm 4CNS 3Endocrine 2Other hematologic neoplasm 1NET 1Lymphoid 1

Conditions

Neuroendocrine Tumors 2Urogenital Neoplasms 1Turcot syndrome 1Stomach Neoplasms 1Sarcoma 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasms, Squamous Cell 1Multiple Myeloma 1Microsatellite Instability 1Mesothelioma 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Merkel Cell 1Breast Neoplasms 1

Interventions

tivozanib 1pembrolizumab 1fludarabine 1entrectinib 1atezolizumab 1alectinib 1aldesleukin 1Quality of Life 1Patient Reported Outcome Measures 1Molecular Diagnostic Techniques 1Magnetic Resonance Spectroscopy 1Immunotherapy 1Fluorodeoxyglucose F18 1FAPI-46 1Drug Therapy 1Cyclophosphamide 1Biological Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Ovarian Neoplasms × fludarabine × NET × Clear all
NCT03412877 2026-05-29

Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer

National Institutes of Health Clinical Center (CC)

Phase 2 Recruiting
285 enrolled
BreastEndocrineGynecologicNETPlasma cellThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Multiple Myeloma, Ovarian Neoplasms, Urogenital Neoplasms, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡